Servier et Day One Biopharmaceuticals annoncent un accord d'acquisition qui renforce le portefeuille de Servier dans les cancers rares
Friday, March 6, 2026 · first reported by PR Newswire
Non-English article (French). Servier acquires Day One Biopharmaceuticals to strengthen its rare cancer portfolio and expand pipeline in pediatric low-grade glioma and other cancers. While M&A is high-signal, this is primarily a corporate acquisition and pharma business development, with limited relevance to fund operations unless structured as fund-backed deal.
- Firm
- Servier
- Also named
- Day One Biopharmaceuticals
The summary and fields above are extracted from the published reports and can contain errors. The linked articles are the source of record.
Coverage
1 sourceMore in Deals
From the same day- Blackstone and Ares provide $5bn private credit financing for Thoma Bravo WWEX dealPrivate Equity Wire
- Advent discloses rejected $1.52bn bid for UK aerospace supplier SeniorPrivate Equity Wire
- Roark mulls $2bn IPO for Dunkin’ owner Inspire BrandsPrivate Equity Wire
- Athora Holding Ltd. secures €3.5 billion of common equity commitments and receives regulatory approval for Pension Insurance Corporation Group Limited acquisitionPR Newswire
- Wynnchurch-backed ORS Nasco scoops up industrial wholesalers AD Member Supply and AlliancePE Hub
- Greenbelt-backed Saber Power snaps up Bounds ConstructionPE Hub